Since TME can be changed from tumor-friendly to tumor-suppressive by switching phenotypes from M2 to M1, IL-6-mediated phenotypic transformation of macrophages may serve as a novel therapeutic target in the PROC. This evidence concerns the gene IL6 and neoplasm.